DRD2 and schizophrenia: Therefore, a medication that combines potent 5-HT2A receptor antagonism with optimal dopamine D2 receptor modulation, and the dopamine D3 receptor antagonism activity may present an ideal balance of dopaminergic and serotonergic neurotransmitter for the treatment of schizophrenia.